nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP3A4—Thiotepa—urinary bladder cancer	0.0456	0.402	CbGbCtD
Bexarotene—CYP2C9—Fluorouracil—urinary bladder cancer	0.0255	0.224	CbGbCtD
Bexarotene—CYP2C9—Cisplatin—urinary bladder cancer	0.0216	0.191	CbGbCtD
Bexarotene—CYP3A4—Etoposide—urinary bladder cancer	0.0124	0.109	CbGbCtD
Bexarotene—CYP3A4—Doxorubicin—urinary bladder cancer	0.00843	0.0743	CbGbCtD
Bexarotene—RXRG—prostate gland—urinary bladder cancer	0.00477	0.216	CbGeAlD
Bexarotene—RXRA—renal system—urinary bladder cancer	0.0037	0.168	CbGeAlD
Bexarotene—CYP2C9—urine—urinary bladder cancer	0.00367	0.166	CbGeAlD
Bexarotene—RXRA—female reproductive system—urinary bladder cancer	0.00297	0.134	CbGeAlD
Bexarotene—CYP3A4—urine—urinary bladder cancer	0.0028	0.127	CbGeAlD
Bexarotene—RXRB—vagina—urinary bladder cancer	0.00221	0.1	CbGeAlD
Bexarotene—CYP2C9—female reproductive system—urinary bladder cancer	0.000719	0.0326	CbGeAlD
Bexarotene—CYP3A4—renal system—urinary bladder cancer	0.000685	0.031	CbGeAlD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NCOR1—urinary bladder cancer	0.00067	0.0028	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.00066	0.00276	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.00066	0.00276	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—PPARG—urinary bladder cancer	0.000652	0.00272	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000651	0.00272	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000646	0.0027	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—CREBBP—urinary bladder cancer	0.000627	0.00262	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000604	0.00252	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—CDKN1A—urinary bladder cancer	0.000602	0.00251	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—NCOR1—urinary bladder cancer	0.000599	0.0025	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000596	0.00249	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—GSTP1—urinary bladder cancer	0.000594	0.00248	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000578	0.00241	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000575	0.0024	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.00057	0.00238	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.00056	0.00234	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000559	0.00233	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—urinary bladder cancer	0.000559	0.00233	CbGpPWpGaD
Bexarotene—RXRA—Circadian Clock—EP300—urinary bladder cancer	0.000559	0.00233	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CNTN2—urinary bladder cancer	0.00055	0.0023	CbGpPWpGaD
Bexarotene—RXRA—Organelle biogenesis and maintenance—NCOR1—urinary bladder cancer	0.000549	0.00229	CbGpPWpGaD
Bexarotene—CYP3A4—female reproductive system—urinary bladder cancer	0.000548	0.0248	CbGeAlD
Bexarotene—RXRA—NRF2 pathway—GSTM1—urinary bladder cancer	0.000546	0.00228	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000544	0.00227	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000543	0.00227	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—FAS—urinary bladder cancer	0.000537	0.00224	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000536	0.00224	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—GSTP1—urinary bladder cancer	0.000521	0.00217	CbGpPWpGaD
Bexarotene—RXRA—Orphan transporters—CREBBP—urinary bladder cancer	0.000493	0.00206	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—PPARG—urinary bladder cancer	0.00049	0.00205	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	0.00048	0.002	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—GSTM1—urinary bladder cancer	0.000479	0.002	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—CREBBP—urinary bladder cancer	0.000471	0.00197	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000468	0.00196	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000467	0.00195	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—TNF—urinary bladder cancer	0.000465	0.00194	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.000461	0.00193	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	0.000461	0.00193	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00046	0.00192	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000459	0.00192	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000453	0.00189	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000453	0.00189	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—urinary bladder cancer	0.000449	0.00187	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000446	0.00186	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000445	0.00186	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000435	0.00182	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000435	0.00182	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000429	0.00179	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—PPARG—urinary bladder cancer	0.000429	0.00179	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—EP300—urinary bladder cancer	0.000427	0.00178	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000419	0.00175	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—RB1—urinary bladder cancer	0.000411	0.00171	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—IGF1—urinary bladder cancer	0.000407	0.0017	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000398	0.00166	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000395	0.00165	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000393	0.00164	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000381	0.00159	CbGpPWpGaD
Bexarotene—RXRA—Organelle biogenesis and maintenance—CREBBP—urinary bladder cancer	0.000378	0.00158	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000362	0.00151	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000359	0.0015	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000357	0.00149	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000354	0.00148	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.00035	0.00146	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000349	0.00146	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000347	0.00145	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—urinary bladder cancer	0.000346	0.00145	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000346	0.00144	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.000331	0.00138	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.00033	0.00138	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—EP300—urinary bladder cancer	0.000321	0.00134	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.00032	0.00133	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—SMC1A—urinary bladder cancer	0.000319	0.00133	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTZ1—urinary bladder cancer	0.000319	0.00133	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000318	0.00133	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	0.000314	0.00131	CbGpPWpGaD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000309	0.00129	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000307	0.00128	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.000303	0.00126	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTO2—urinary bladder cancer	0.000302	0.00126	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NAT1—urinary bladder cancer	0.000302	0.00126	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000301	0.00126	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—SMC1A—urinary bladder cancer	0.0003	0.00125	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.000299	0.00125	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000297	0.00124	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—CDKN1A—urinary bladder cancer	0.000295	0.00123	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000289	0.00121	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000289	0.00121	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000283	0.00118	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000281	0.00117	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—ESR2—urinary bladder cancer	0.000278	0.00116	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—UGT2B7—urinary bladder cancer	0.000277	0.00115	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000271	0.00113	CbGpPWpGaD
Bexarotene—Pneumonia—Doxorubicin—urinary bladder cancer	0.000266	0.000425	CcSEcCtD
Bexarotene—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000266	0.000425	CcSEcCtD
Bexarotene—Pruritus—Fluorouracil—urinary bladder cancer	0.000265	0.000424	CcSEcCtD
Bexarotene—RXRB—Gene Expression—ESR2—urinary bladder cancer	0.000262	0.00109	CbGpPWpGaD
Bexarotene—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000261	0.000418	CcSEcCtD
Bexarotene—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00026	0.000417	CcSEcCtD
Bexarotene—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000259	0.000414	CcSEcCtD
Bexarotene—Haemoglobin—Epirubicin—urinary bladder cancer	0.000258	0.000412	CcSEcCtD
Bexarotene—Jaundice—Doxorubicin—urinary bladder cancer	0.000258	0.000412	CcSEcCtD
Bexarotene—Stomatitis—Doxorubicin—urinary bladder cancer	0.000258	0.000412	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000257	0.00107	CbGpPWpGaD
Bexarotene—Rhinitis—Epirubicin—urinary bladder cancer	0.000257	0.000411	CcSEcCtD
Bexarotene—Abdominal pain—Etoposide—urinary bladder cancer	0.000257	0.000411	CcSEcCtD
Bexarotene—Body temperature increased—Etoposide—urinary bladder cancer	0.000257	0.000411	CcSEcCtD
Bexarotene—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000257	0.000411	CcSEcCtD
Bexarotene—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000257	0.000411	CcSEcCtD
Bexarotene—Haemorrhage—Epirubicin—urinary bladder cancer	0.000256	0.00041	CcSEcCtD
Bexarotene—Eye disorder—Methotrexate—urinary bladder cancer	0.000256	0.00041	CcSEcCtD
Bexarotene—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000256	0.00041	CcSEcCtD
Bexarotene—Tinnitus—Methotrexate—urinary bladder cancer	0.000255	0.000409	CcSEcCtD
Bexarotene—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000255	0.000408	CcSEcCtD
Bexarotene—Asthenia—Cisplatin—urinary bladder cancer	0.000254	0.000407	CcSEcCtD
Bexarotene—Pharyngitis—Epirubicin—urinary bladder cancer	0.000254	0.000407	CcSEcCtD
Bexarotene—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000254	0.000407	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000254	0.00106	CbGpPWpGaD
Bexarotene—Sweating—Doxorubicin—urinary bladder cancer	0.000253	0.000405	CcSEcCtD
Bexarotene—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000253	0.000405	CcSEcCtD
Bexarotene—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000253	0.000404	CcSEcCtD
Bexarotene—Haematuria—Doxorubicin—urinary bladder cancer	0.000252	0.000403	CcSEcCtD
Bexarotene—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000252	0.000403	CcSEcCtD
Bexarotene—Urethral disorder—Epirubicin—urinary bladder cancer	0.000251	0.000402	CcSEcCtD
Bexarotene—Epistaxis—Doxorubicin—urinary bladder cancer	0.000249	0.000399	CcSEcCtD
Bexarotene—RXRA—Metabolism—CYP4B1—urinary bladder cancer	0.000249	0.00104	CbGpPWpGaD
Bexarotene—Angiopathy—Methotrexate—urinary bladder cancer	0.000249	0.000398	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000248	0.00104	CbGpPWpGaD
Bexarotene—Sinusitis—Doxorubicin—urinary bladder cancer	0.000248	0.000397	CcSEcCtD
Bexarotene—Dizziness—Fluorouracil—urinary bladder cancer	0.000247	0.000396	CcSEcCtD
Bexarotene—Chills—Methotrexate—urinary bladder cancer	0.000246	0.000393	CcSEcCtD
Bexarotene—Diarrhoea—Cisplatin—urinary bladder cancer	0.000243	0.000388	CcSEcCtD
Bexarotene—Alopecia—Methotrexate—urinary bladder cancer	0.000242	0.000387	CcSEcCtD
Bexarotene—Vomiting—Gemcitabine—urinary bladder cancer	0.000242	0.000387	CcSEcCtD
Bexarotene—Rash—Gemcitabine—urinary bladder cancer	0.00024	0.000384	CcSEcCtD
Bexarotene—Dermatitis—Gemcitabine—urinary bladder cancer	0.00024	0.000384	CcSEcCtD
Bexarotene—Eye disorder—Epirubicin—urinary bladder cancer	0.00024	0.000383	CcSEcCtD
Bexarotene—Hypersensitivity—Etoposide—urinary bladder cancer	0.000239	0.000383	CcSEcCtD
Bexarotene—Tinnitus—Epirubicin—urinary bladder cancer	0.000239	0.000382	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000239	0.000996	CbGpPWpGaD
Bexarotene—Malnutrition—Methotrexate—urinary bladder cancer	0.000238	0.000382	CcSEcCtD
Bexarotene—Erythema—Methotrexate—urinary bladder cancer	0.000238	0.000382	CcSEcCtD
Bexarotene—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000238	0.000381	CcSEcCtD
Bexarotene—Headache—Gemcitabine—urinary bladder cancer	0.000238	0.000381	CcSEcCtD
Bexarotene—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000238	0.000381	CcSEcCtD
Bexarotene—Vomiting—Fluorouracil—urinary bladder cancer	0.000238	0.000381	CcSEcCtD
Bexarotene—Rhinitis—Doxorubicin—urinary bladder cancer	0.000238	0.00038	CcSEcCtD
Bexarotene—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000237	0.00038	CcSEcCtD
Bexarotene—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000236	0.000378	CcSEcCtD
Bexarotene—Rash—Fluorouracil—urinary bladder cancer	0.000236	0.000377	CcSEcCtD
Bexarotene—Dermatitis—Fluorouracil—urinary bladder cancer	0.000236	0.000377	CcSEcCtD
Bexarotene—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000235	0.000377	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000235	0.000982	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—SLC19A1—urinary bladder cancer	0.000235	0.000982	CbGpPWpGaD
Bexarotene—Headache—Fluorouracil—urinary bladder cancer	0.000234	0.000375	CcSEcCtD
Bexarotene—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000234	0.000375	CcSEcCtD
Bexarotene—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000234	0.000374	CcSEcCtD
Bexarotene—Dysgeusia—Methotrexate—urinary bladder cancer	0.000233	0.000374	CcSEcCtD
Bexarotene—Asthenia—Etoposide—urinary bladder cancer	0.000233	0.000373	CcSEcCtD
Bexarotene—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000233	0.000373	CcSEcCtD
Bexarotene—Angiopathy—Epirubicin—urinary bladder cancer	0.000233	0.000372	CcSEcCtD
Bexarotene—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000232	0.000372	CcSEcCtD
Bexarotene—Back pain—Methotrexate—urinary bladder cancer	0.000231	0.000369	CcSEcCtD
Bexarotene—Chills—Epirubicin—urinary bladder cancer	0.00023	0.000368	CcSEcCtD
Bexarotene—Pruritus—Etoposide—urinary bladder cancer	0.00023	0.000368	CcSEcCtD
Bexarotene—RXRA—Metabolism—PRSS3—urinary bladder cancer	0.000229	0.000957	CbGpPWpGaD
Bexarotene—Arrhythmia—Epirubicin—urinary bladder cancer	0.000229	0.000366	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—TNF—urinary bladder cancer	0.000228	0.000951	CbGpPWpGaD
Bexarotene—Alopecia—Epirubicin—urinary bladder cancer	0.000227	0.000362	CcSEcCtD
Bexarotene—Nausea—Gemcitabine—urinary bladder cancer	0.000226	0.000362	CcSEcCtD
Bexarotene—Vomiting—Cisplatin—urinary bladder cancer	0.000225	0.000361	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.000224	0.000936	CbGpPWpGaD
Bexarotene—Rash—Cisplatin—urinary bladder cancer	0.000224	0.000358	CcSEcCtD
Bexarotene—Dermatitis—Cisplatin—urinary bladder cancer	0.000223	0.000357	CcSEcCtD
Bexarotene—Erythema—Epirubicin—urinary bladder cancer	0.000223	0.000357	CcSEcCtD
Bexarotene—Malnutrition—Epirubicin—urinary bladder cancer	0.000223	0.000357	CcSEcCtD
Bexarotene—Diarrhoea—Etoposide—urinary bladder cancer	0.000222	0.000356	CcSEcCtD
Bexarotene—Nausea—Fluorouracil—urinary bladder cancer	0.000222	0.000356	CcSEcCtD
Bexarotene—Eye disorder—Doxorubicin—urinary bladder cancer	0.000222	0.000355	CcSEcCtD
Bexarotene—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000221	0.000354	CcSEcCtD
Bexarotene—Tinnitus—Doxorubicin—urinary bladder cancer	0.000221	0.000354	CcSEcCtD
Bexarotene—Anaemia—Methotrexate—urinary bladder cancer	0.00022	0.000353	CcSEcCtD
Bexarotene—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00022	0.000352	CcSEcCtD
Bexarotene—Flatulence—Epirubicin—urinary bladder cancer	0.00022	0.000352	CcSEcCtD
Bexarotene—Tension—Epirubicin—urinary bladder cancer	0.000219	0.00035	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000219	0.000913	CbGpPWpGaD
Bexarotene—Dysgeusia—Epirubicin—urinary bladder cancer	0.000219	0.00035	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	0.000217	0.000905	CbGpPWpGaD
Bexarotene—Nervousness—Epirubicin—urinary bladder cancer	0.000217	0.000347	CcSEcCtD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000216	0.000903	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	0.000216	0.000903	CbGpPWpGaD
Bexarotene—Back pain—Epirubicin—urinary bladder cancer	0.000216	0.000345	CcSEcCtD
Bexarotene—Angiopathy—Doxorubicin—urinary bladder cancer	0.000215	0.000344	CcSEcCtD
Bexarotene—Malaise—Methotrexate—urinary bladder cancer	0.000215	0.000344	CcSEcCtD
Bexarotene—Dizziness—Etoposide—urinary bladder cancer	0.000215	0.000344	CcSEcCtD
Bexarotene—RXRG—Gene Expression—NCOR1—urinary bladder cancer	0.000215	0.000897	CbGpPWpGaD
Bexarotene—Muscle spasms—Epirubicin—urinary bladder cancer	0.000215	0.000343	CcSEcCtD
Bexarotene—Vertigo—Methotrexate—urinary bladder cancer	0.000214	0.000343	CcSEcCtD
Bexarotene—Leukopenia—Methotrexate—urinary bladder cancer	0.000213	0.000342	CcSEcCtD
Bexarotene—Chills—Doxorubicin—urinary bladder cancer	0.000213	0.000341	CcSEcCtD
Bexarotene—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000212	0.000339	CcSEcCtD
Bexarotene—Nausea—Cisplatin—urinary bladder cancer	0.000211	0.000337	CcSEcCtD
Bexarotene—Alopecia—Doxorubicin—urinary bladder cancer	0.00021	0.000335	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000209	0.000872	CbGpPWpGaD
Bexarotene—Cough—Methotrexate—urinary bladder cancer	0.000208	0.000333	CcSEcCtD
Bexarotene—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000207	0.000331	CcSEcCtD
Bexarotene—Vomiting—Etoposide—urinary bladder cancer	0.000207	0.000331	CcSEcCtD
Bexarotene—Erythema—Doxorubicin—urinary bladder cancer	0.000206	0.00033	CcSEcCtD
Bexarotene—Malnutrition—Doxorubicin—urinary bladder cancer	0.000206	0.00033	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	0.000206	0.000862	CbGpPWpGaD
Bexarotene—Anaemia—Epirubicin—urinary bladder cancer	0.000206	0.00033	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—NCOR1—urinary bladder cancer	0.000206	0.000859	CbGpPWpGaD
Bexarotene—Agitation—Epirubicin—urinary bladder cancer	0.000205	0.000328	CcSEcCtD
Bexarotene—Rash—Etoposide—urinary bladder cancer	0.000205	0.000328	CcSEcCtD
Bexarotene—Dermatitis—Etoposide—urinary bladder cancer	0.000205	0.000327	CcSEcCtD
Bexarotene—Headache—Etoposide—urinary bladder cancer	0.000204	0.000326	CcSEcCtD
Bexarotene—Flatulence—Doxorubicin—urinary bladder cancer	0.000203	0.000326	CcSEcCtD
Bexarotene—Arthralgia—Methotrexate—urinary bladder cancer	0.000203	0.000325	CcSEcCtD
Bexarotene—Myalgia—Methotrexate—urinary bladder cancer	0.000203	0.000325	CcSEcCtD
Bexarotene—Chest pain—Methotrexate—urinary bladder cancer	0.000203	0.000325	CcSEcCtD
Bexarotene—Tension—Doxorubicin—urinary bladder cancer	0.000203	0.000324	CcSEcCtD
Bexarotene—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000202	0.000324	CcSEcCtD
Bexarotene—RXRB—Gene Expression—NCOR1—urinary bladder cancer	0.000202	0.000843	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—ERCC2—urinary bladder cancer	0.000202	0.000843	CbGpPWpGaD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000202	0.000323	CcSEcCtD
Bexarotene—Malaise—Epirubicin—urinary bladder cancer	0.000201	0.000322	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	0.000201	0.000838	CbGpPWpGaD
Bexarotene—Discomfort—Methotrexate—urinary bladder cancer	0.000201	0.000321	CcSEcCtD
Bexarotene—Nervousness—Doxorubicin—urinary bladder cancer	0.000201	0.000321	CcSEcCtD
Bexarotene—Vertigo—Epirubicin—urinary bladder cancer	0.0002	0.000321	CcSEcCtD
Bexarotene—Syncope—Epirubicin—urinary bladder cancer	0.0002	0.00032	CcSEcCtD
Bexarotene—Leukopenia—Epirubicin—urinary bladder cancer	0.0002	0.00032	CcSEcCtD
Bexarotene—Back pain—Doxorubicin—urinary bladder cancer	0.0002	0.00032	CcSEcCtD
Bexarotene—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000198	0.000318	CcSEcCtD
Bexarotene—Palpitations—Epirubicin—urinary bladder cancer	0.000197	0.000316	CcSEcCtD
Bexarotene—Confusional state—Methotrexate—urinary bladder cancer	0.000196	0.000314	CcSEcCtD
Bexarotene—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000196	0.000314	CcSEcCtD
Bexarotene—Cough—Epirubicin—urinary bladder cancer	0.000195	0.000312	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000194	0.000812	CbGpPWpGaD
Bexarotene—Infection—Methotrexate—urinary bladder cancer	0.000193	0.000309	CcSEcCtD
Bexarotene—Nausea—Etoposide—urinary bladder cancer	0.000193	0.000309	CcSEcCtD
Bexarotene—Hypertension—Epirubicin—urinary bladder cancer	0.000193	0.000308	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000192	0.000801	CbGpPWpGaD
Bexarotene—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000192	0.000307	CcSEcCtD
Bexarotene—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000191	0.000305	CcSEcCtD
Bexarotene—Anaemia—Doxorubicin—urinary bladder cancer	0.000191	0.000305	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000191	0.000796	CbGpPWpGaD
Bexarotene—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000191	0.000305	CcSEcCtD
Bexarotene—Myalgia—Epirubicin—urinary bladder cancer	0.00019	0.000304	CcSEcCtD
Bexarotene—Chest pain—Epirubicin—urinary bladder cancer	0.00019	0.000304	CcSEcCtD
Bexarotene—Arthralgia—Epirubicin—urinary bladder cancer	0.00019	0.000304	CcSEcCtD
Bexarotene—RXRB—Gene Expression—ERCC2—urinary bladder cancer	0.00019	0.000793	CbGpPWpGaD
Bexarotene—Agitation—Doxorubicin—urinary bladder cancer	0.00019	0.000304	CcSEcCtD
Bexarotene—Anxiety—Epirubicin—urinary bladder cancer	0.000189	0.000303	CcSEcCtD
Bexarotene—Skin disorder—Methotrexate—urinary bladder cancer	0.000189	0.000302	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000189	0.000302	CcSEcCtD
Bexarotene—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000188	0.000301	CcSEcCtD
Bexarotene—Discomfort—Epirubicin—urinary bladder cancer	0.000188	0.0003	CcSEcCtD
Bexarotene—Malaise—Doxorubicin—urinary bladder cancer	0.000186	0.000298	CcSEcCtD
Bexarotene—Dry mouth—Epirubicin—urinary bladder cancer	0.000186	0.000297	CcSEcCtD
Bexarotene—Vertigo—Doxorubicin—urinary bladder cancer	0.000185	0.000297	CcSEcCtD
Bexarotene—Anorexia—Methotrexate—urinary bladder cancer	0.000185	0.000297	CcSEcCtD
Bexarotene—Syncope—Doxorubicin—urinary bladder cancer	0.000185	0.000296	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000185	0.000772	CbGpPWpGaD
Bexarotene—Leukopenia—Doxorubicin—urinary bladder cancer	0.000185	0.000296	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000184	0.000767	CbGpPWpGaD
Bexarotene—Confusional state—Epirubicin—urinary bladder cancer	0.000184	0.000294	CcSEcCtD
Bexarotene—RXRA—Metabolism—TYMP—urinary bladder cancer	0.000183	0.000765	CbGpPWpGaD
Bexarotene—Palpitations—Doxorubicin—urinary bladder cancer	0.000182	0.000292	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000182	0.000761	CbGpPWpGaD
Bexarotene—Oedema—Epirubicin—urinary bladder cancer	0.000182	0.000291	CcSEcCtD
Bexarotene—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000181	0.00029	CcSEcCtD
Bexarotene—Infection—Epirubicin—urinary bladder cancer	0.000181	0.00029	CcSEcCtD
Bexarotene—Cough—Doxorubicin—urinary bladder cancer	0.00018	0.000288	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	0.00018	0.000751	CbGpPWpGaD
Bexarotene—Shock—Epirubicin—urinary bladder cancer	0.000179	0.000287	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000179	0.000746	CbGpPWpGaD
Bexarotene—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000179	0.000286	CcSEcCtD
Bexarotene—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000178	0.000285	CcSEcCtD
Bexarotene—Hypertension—Doxorubicin—urinary bladder cancer	0.000178	0.000285	CcSEcCtD
Bexarotene—Tachycardia—Epirubicin—urinary bladder cancer	0.000178	0.000284	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000177	0.000284	CcSEcCtD
Bexarotene—Skin disorder—Epirubicin—urinary bladder cancer	0.000177	0.000283	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000176	0.000736	CbGpPWpGaD
Bexarotene—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000176	0.000282	CcSEcCtD
Bexarotene—Insomnia—Methotrexate—urinary bladder cancer	0.000176	0.000282	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000176	0.000735	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	0.000176	0.000734	CbGpPWpGaD
Bexarotene—Chest pain—Doxorubicin—urinary bladder cancer	0.000176	0.000281	CcSEcCtD
Bexarotene—Myalgia—Doxorubicin—urinary bladder cancer	0.000176	0.000281	CcSEcCtD
Bexarotene—Arthralgia—Doxorubicin—urinary bladder cancer	0.000176	0.000281	CcSEcCtD
Bexarotene—Anxiety—Doxorubicin—urinary bladder cancer	0.000175	0.00028	CcSEcCtD
Bexarotene—Paraesthesia—Methotrexate—urinary bladder cancer	0.000175	0.00028	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000175	0.000279	CcSEcCtD
Bexarotene—Discomfort—Doxorubicin—urinary bladder cancer	0.000174	0.000278	CcSEcCtD
Bexarotene—Anorexia—Epirubicin—urinary bladder cancer	0.000174	0.000278	CcSEcCtD
Bexarotene—Dyspnoea—Methotrexate—urinary bladder cancer	0.000173	0.000278	CcSEcCtD
Bexarotene—Somnolence—Methotrexate—urinary bladder cancer	0.000173	0.000277	CcSEcCtD
Bexarotene—Dry mouth—Doxorubicin—urinary bladder cancer	0.000172	0.000275	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000172	0.000717	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000171	0.000716	CbGpPWpGaD
Bexarotene—Dyspepsia—Methotrexate—urinary bladder cancer	0.000171	0.000274	CcSEcCtD
Bexarotene—Confusional state—Doxorubicin—urinary bladder cancer	0.00017	0.000272	CcSEcCtD
Bexarotene—Decreased appetite—Methotrexate—urinary bladder cancer	0.000169	0.000271	CcSEcCtD
Bexarotene—RXRG—Gene Expression—ESR1—urinary bladder cancer	0.000169	0.000704	CbGpPWpGaD
Bexarotene—Oedema—Doxorubicin—urinary bladder cancer	0.000168	0.00027	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000168	0.000269	CcSEcCtD
Bexarotene—Fatigue—Methotrexate—urinary bladder cancer	0.000168	0.000268	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	0.000168	0.000699	CbGpPWpGaD
Bexarotene—Infection—Doxorubicin—urinary bladder cancer	0.000167	0.000268	CcSEcCtD
Bexarotene—Pain—Methotrexate—urinary bladder cancer	0.000166	0.000266	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	0.000166	0.000694	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000166	0.000266	CcSEcCtD
Bexarotene—Shock—Doxorubicin—urinary bladder cancer	0.000166	0.000265	CcSEcCtD
Bexarotene—RXRA—Metabolism—NAT2—urinary bladder cancer	0.000166	0.000692	CbGpPWpGaD
Bexarotene—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000165	0.000264	CcSEcCtD
Bexarotene—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000165	0.000264	CcSEcCtD
Bexarotene—Insomnia—Epirubicin—urinary bladder cancer	0.000165	0.000264	CcSEcCtD
Bexarotene—Tachycardia—Doxorubicin—urinary bladder cancer	0.000164	0.000263	CcSEcCtD
Bexarotene—Skin disorder—Doxorubicin—urinary bladder cancer	0.000164	0.000262	CcSEcCtD
Bexarotene—Paraesthesia—Epirubicin—urinary bladder cancer	0.000164	0.000262	CcSEcCtD
Bexarotene—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000163	0.000261	CcSEcCtD
Bexarotene—Dyspnoea—Epirubicin—urinary bladder cancer	0.000162	0.00026	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—CDK4—urinary bladder cancer	0.000162	0.000678	CbGpPWpGaD
Bexarotene—Somnolence—Epirubicin—urinary bladder cancer	0.000162	0.000259	CcSEcCtD
Bexarotene—Anorexia—Doxorubicin—urinary bladder cancer	0.000161	0.000257	CcSEcCtD
Bexarotene—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00016	0.000257	CcSEcCtD
Bexarotene—Dyspepsia—Epirubicin—urinary bladder cancer	0.00016	0.000257	CcSEcCtD
Bexarotene—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000159	0.000255	CcSEcCtD
Bexarotene—RXRB—Gene Expression—ESR1—urinary bladder cancer	0.000159	0.000662	CbGpPWpGaD
Bexarotene—Decreased appetite—Epirubicin—urinary bladder cancer	0.000158	0.000253	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000157	0.000252	CcSEcCtD
Bexarotene—Fatigue—Epirubicin—urinary bladder cancer	0.000157	0.000251	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000157	0.000654	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—SMC1A—urinary bladder cancer	0.000156	0.000653	CbGpPWpGaD
Bexarotene—Pain—Epirubicin—urinary bladder cancer	0.000156	0.000249	CcSEcCtD
Bexarotene—Constipation—Epirubicin—urinary bladder cancer	0.000156	0.000249	CcSEcCtD
Bexarotene—RXRG—Gene Expression—PPARG—urinary bladder cancer	0.000154	0.000643	CbGpPWpGaD
Bexarotene—Body temperature increased—Methotrexate—urinary bladder cancer	0.000154	0.000246	CcSEcCtD
Bexarotene—Abdominal pain—Methotrexate—urinary bladder cancer	0.000154	0.000246	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000154	0.000246	CcSEcCtD
Bexarotene—Insomnia—Doxorubicin—urinary bladder cancer	0.000152	0.000244	CcSEcCtD
Bexarotene—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000151	0.000242	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000151	0.000628	CbGpPWpGaD
Bexarotene—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00015	0.00024	CcSEcCtD
Bexarotene—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00015	0.00024	CcSEcCtD
Bexarotene—Somnolence—Doxorubicin—urinary bladder cancer	0.00015	0.00024	CcSEcCtD
Bexarotene—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000149	0.000238	CcSEcCtD
Bexarotene—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000148	0.000237	CcSEcCtD
Bexarotene—RXRG—Gene Expression—CREBBP—urinary bladder cancer	0.000148	0.000617	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	0.000148	0.000617	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—PPARG—urinary bladder cancer	0.000147	0.000616	CbGpPWpGaD
Bexarotene—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000146	0.000234	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000145	0.000233	CcSEcCtD
Bexarotene—Fatigue—Doxorubicin—urinary bladder cancer	0.000145	0.000232	CcSEcCtD
Bexarotene—RXRB—Gene Expression—PPARG—urinary bladder cancer	0.000145	0.000604	CbGpPWpGaD
Bexarotene—Constipation—Doxorubicin—urinary bladder cancer	0.000144	0.000231	CcSEcCtD
Bexarotene—Pain—Doxorubicin—urinary bladder cancer	0.000144	0.000231	CcSEcCtD
Bexarotene—Body temperature increased—Epirubicin—urinary bladder cancer	0.000144	0.00023	CcSEcCtD
Bexarotene—Abdominal pain—Epirubicin—urinary bladder cancer	0.000144	0.00023	CcSEcCtD
Bexarotene—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000143	0.000229	CcSEcCtD
Bexarotene—RXRA—Metabolism—RRM2—urinary bladder cancer	0.000143	0.000597	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CREBBP—urinary bladder cancer	0.000142	0.000591	CbGpPWpGaD
Bexarotene—Asthenia—Methotrexate—urinary bladder cancer	0.00014	0.000223	CcSEcCtD
Bexarotene—RXRB—Gene Expression—CREBBP—urinary bladder cancer	0.000139	0.00058	CbGpPWpGaD
Bexarotene—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000139	0.000222	CcSEcCtD
Bexarotene—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000138	0.00022	CcSEcCtD
Bexarotene—Pruritus—Methotrexate—urinary bladder cancer	0.000138	0.00022	CcSEcCtD
Bexarotene—RXRA—Gene Expression—ESR2—urinary bladder cancer	0.000136	0.000569	CbGpPWpGaD
Bexarotene—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000134	0.000215	CcSEcCtD
Bexarotene—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000133	0.000213	CcSEcCtD
Bexarotene—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000133	0.000213	CcSEcCtD
Bexarotene—Diarrhoea—Methotrexate—urinary bladder cancer	0.000133	0.000213	CcSEcCtD
Bexarotene—RXRA—Metabolism—ENO2—urinary bladder cancer	0.000132	0.000553	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—HPGDS—urinary bladder cancer	0.000132	0.000553	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000132	0.00055	CbGpPWpGaD
Bexarotene—Asthenia—Epirubicin—urinary bladder cancer	0.000131	0.000209	CcSEcCtD
Bexarotene—Pruritus—Epirubicin—urinary bladder cancer	0.000129	0.000206	CcSEcCtD
Bexarotene—Dizziness—Methotrexate—urinary bladder cancer	0.000129	0.000206	CcSEcCtD
Bexarotene—RXRA—Metabolism—GSTT1—urinary bladder cancer	0.000128	0.000536	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000128	0.000535	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—RHOA—urinary bladder cancer	0.000128	0.000535	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000127	0.000528	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000126	0.000528	CbGpPWpGaD
Bexarotene—Diarrhoea—Epirubicin—urinary bladder cancer	0.000125	0.000199	CcSEcCtD
Bexarotene—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000124	0.000199	CcSEcCtD
Bexarotene—Vomiting—Methotrexate—urinary bladder cancer	0.000124	0.000198	CcSEcCtD
Bexarotene—Rash—Methotrexate—urinary bladder cancer	0.000123	0.000196	CcSEcCtD
Bexarotene—Dermatitis—Methotrexate—urinary bladder cancer	0.000123	0.000196	CcSEcCtD
Bexarotene—Headache—Methotrexate—urinary bladder cancer	0.000122	0.000195	CcSEcCtD
Bexarotene—Asthenia—Doxorubicin—urinary bladder cancer	0.000121	0.000193	CcSEcCtD
Bexarotene—Dizziness—Epirubicin—urinary bladder cancer	0.00012	0.000193	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.00012	0.000502	CbGpPWpGaD
Bexarotene—Pruritus—Doxorubicin—urinary bladder cancer	0.000119	0.000191	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000119	0.000497	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—ERBB2—urinary bladder cancer	0.000119	0.000495	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000118	0.000492	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000116	0.000485	CbGpPWpGaD
Bexarotene—Vomiting—Epirubicin—urinary bladder cancer	0.000116	0.000185	CcSEcCtD
Bexarotene—Nausea—Methotrexate—urinary bladder cancer	0.000116	0.000185	CcSEcCtD
Bexarotene—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000115	0.000184	CcSEcCtD
Bexarotene—Rash—Epirubicin—urinary bladder cancer	0.000115	0.000184	CcSEcCtD
Bexarotene—Dermatitis—Epirubicin—urinary bladder cancer	0.000115	0.000184	CcSEcCtD
Bexarotene—Headache—Epirubicin—urinary bladder cancer	0.000114	0.000183	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000113	0.000471	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000113	0.000471	CbGpPWpGaD
Bexarotene—Dizziness—Doxorubicin—urinary bladder cancer	0.000111	0.000178	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000111	0.000464	CbGpPWpGaD
Bexarotene—Nausea—Epirubicin—urinary bladder cancer	0.000108	0.000173	CcSEcCtD
Bexarotene—Vomiting—Doxorubicin—urinary bladder cancer	0.000107	0.000171	CcSEcCtD
Bexarotene—RXRA—Metabolism—NQO1—urinary bladder cancer	0.000107	0.000446	CbGpPWpGaD
Bexarotene—Rash—Doxorubicin—urinary bladder cancer	0.000106	0.00017	CcSEcCtD
Bexarotene—Dermatitis—Doxorubicin—urinary bladder cancer	0.000106	0.00017	CcSEcCtD
Bexarotene—Headache—Doxorubicin—urinary bladder cancer	0.000106	0.000169	CcSEcCtD
Bexarotene—RXRA—Gene Expression—NCOR1—urinary bladder cancer	0.000105	0.000439	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000104	0.000433	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	0.000103	0.000431	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MMP9—urinary bladder cancer	0.000102	0.000425	CbGpPWpGaD
Bexarotene—Nausea—Doxorubicin—urinary bladder cancer	0.0001	0.00016	CcSEcCtD
Bexarotene—RXRA—Gene Expression—ERCC2—urinary bladder cancer	9.9e-05	0.000413	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EP300—urinary bladder cancer	9.65e-05	0.000403	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—SRC—urinary bladder cancer	9.38e-05	0.000392	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	9.3e-05	0.000388	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.04e-05	0.000377	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—MYC—urinary bladder cancer	8.93e-05	0.000373	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTP1—urinary bladder cancer	8.91e-05	0.000372	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	8.78e-05	0.000367	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MYC—urinary bladder cancer	8.78e-05	0.000366	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.62e-05	0.00036	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	8.56e-05	0.000357	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—TYMS—urinary bladder cancer	8.28e-05	0.000346	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—ESR1—urinary bladder cancer	8.27e-05	0.000345	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—MYC—urinary bladder cancer	8.25e-05	0.000345	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EGFR—urinary bladder cancer	8.22e-05	0.000343	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTM1—urinary bladder cancer	8.18e-05	0.000342	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NCOR1—urinary bladder cancer	8.18e-05	0.000342	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	7.86e-05	0.000328	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GPX1—urinary bladder cancer	7.84e-05	0.000327	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TNF—urinary bladder cancer	7.83e-05	0.000327	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—KRAS—urinary bladder cancer	7.77e-05	0.000324	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ERCC2—urinary bladder cancer	7.7e-05	0.000321	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PPARG—urinary bladder cancer	7.54e-05	0.000315	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.45e-05	0.000311	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.45e-05	0.000311	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—CREBBP—urinary bladder cancer	7.25e-05	0.000303	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—MTHFR—urinary bladder cancer	7.23e-05	0.000302	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.86e-05	0.000286	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TYMP—urinary bladder cancer	6.84e-05	0.000286	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	6.81e-05	0.000284	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—HRAS—urinary bladder cancer	6.6e-05	0.000276	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.57e-05	0.000274	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NAT2—urinary bladder cancer	6.19e-05	0.000258	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.13e-05	0.000256	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PPARG—urinary bladder cancer	5.87e-05	0.000245	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.79e-05	0.000242	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.64e-05	0.000236	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CREBBP—urinary bladder cancer	5.63e-05	0.000235	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—RRM2—urinary bladder cancer	5.34e-05	0.000223	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.95e-05	0.000206	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.95e-05	0.000206	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.92e-05	0.000205	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.8e-05	0.0002	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.72e-05	0.000197	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTGS2—urinary bladder cancer	4.61e-05	0.000193	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.51e-05	0.000188	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MYC—urinary bladder cancer	4.3e-05	0.00018	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.08e-05	0.00017	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTEN—urinary bladder cancer	4.02e-05	0.000168	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.99e-05	0.000166	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.87e-05	0.000161	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—EP300—urinary bladder cancer	3.84e-05	0.00016	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.52e-05	0.000147	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.37e-05	0.000141	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.33e-05	0.000139	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.26e-05	0.000136	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.26e-05	0.000136	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.22e-05	0.000134	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.16e-05	0.000132	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.09e-05	0.000129	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.06e-05	0.000128	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.06e-05	0.000128	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.93e-05	0.000122	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.87e-05	0.00012	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.7e-05	0.000113	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.63e-05	0.00011	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.19e-05	9.16e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.19e-05	9.14e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.1e-05	8.78e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.04e-05	8.51e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.02e-05	8.41e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.02e-05	8.41e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.93e-05	8.06e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.89e-05	7.91e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.78e-05	7.44e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.72e-05	7.19e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.5e-05	6.27e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.44e-05	6.03e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.43e-05	5.98e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.39e-05	5.79e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.14e-05	4.74e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTEN—urinary bladder cancer	9.91e-06	4.14e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.45e-06	3.94e-05	CbGpPWpGaD
